Acclaimed actress Samantha Ruth Prabhu recently announced the conclusion of her filming schedule for the much-anticipated series ‘Citadel India.’ The actress shared her journey on her Instagram Stories, expressing the significance of the 13th of July as a notable date for her. Samantha has been filming for the series in both Serbia and India, alongside co-star Varun Dhawan.
A Testing Journey for Samantha
View this post on Instagram
The past six months have been challenging for Samantha, with back-to-back shooting schedules taking a toll on her health. She has been battling Myositis, an autoimmune condition, making her filming journey particularly tough. She highlighted the last six months as the “longest and hardest” in her Instagram story, illustrating the demanding nature of her professional commitments.
Upcoming ‘Kushi’ and Planned Hiatus
Following ‘Citadel India’, Samantha will next appear in ‘Kushi,’ a romantic drama featuring Vijay Deverakonda, set for a theatrical release on September 1. However, reports suggest a temporary halt to her career thereafter, with the actress planning a year-long break. Samantha’s intention is to focus on her health and seek further treatment, implying she will not sign any new Telugu or Bollywood films for a year.
Possible US Visit and Future Prospects
Reports indicate that Samantha may travel to the US for treatment during her hiatus. However, the actress has not issued an official statement confirming these plans. While fans eagerly await ‘Citadel India’ and ‘Kushi,’ they also express their well-wishes for Samantha’s health and are looking forward to her return post the planned break.
Conclusion
Samantha Ruth Prabhu’s decision to prioritise her health over work reflects a growing trend among celebrities. After wrapping up her demanding schedule for ‘Citadel India,’ she plans to step back for a while, focusing on recovering and rejuvenating. Fans and industry insiders alike await her return, hoping to see the beloved actress bounce back stronger and healthier.
DNP ENTERTAINMENT FOLLOW US: FACEBOOK, INSTAGRAM, and TWITTER.
